Medical Oncology

Interstitial lung disease

Questions discussed in this category

Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?

2 Answers available

Papers discussed in this category

Cancer Treat Rev, 2022 Mar 12

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

Related Topics in Medical Oncology